Remdesivir is one of the most encouraging treatments against SARS-CoV-2 infection. After intravenous infusion, RDV is rapidly metabolized (T1/2 1h) within the cells to its active adenosine triphosphate analogue form (GS-443902) and, then, it can be found in plasma in its nucleoside analogue form (GS-441524). In this real life study we describe the Remdesivir and GS-441524 concentrations at 3 time points in nine ICU patients, through a validated UHPLC-MS/MS method. The observed data confirmed the very rapid conversion of RDV to its metabolite and the quite long half-life of GS-441524. The mean Cmin , Cmax , AUC0-24 , were < 0.24 ng/mL and 122.3 ng/ml, 2637,3 ng/mL and 157,8 ng/ml, 5171.2 ng*h/mL and 3676.5 ng*h/ml respectively for RDV and GS-441524. Three out of nine patients achieved a Cmax > 2610 ng/mL and 140 ng/mL and AUC0-24 > 1560 ng*h/mL and 2230 ng*h/mL for RDV and GS-441524, respectively. The mean T1/2 value for GS-441524 was 26.3 h. Although the low number of patients, these data can represent an interesting preliminary report of the variability of RDV and GS-441524 concentrations in real-life ICU setting.

Real life Study on the Pharmacokinetic of Remdesivir in ICU patients admitted for Severe COVID-19 Pneumonia

Corcione, Silvia
First
;
De Nicolò, Amedeo;Montrucchio, Giorgia;Scabini, Silvia;Avataneo, Valeria;Bonetto, Chiara;Mornese Pinna, Simone;Cusato, Jessica;Canta, Francesca;Di Perri, Giovanni;Brazzi, Luca;De Rosa, Francesco Giuseppe
Co-last
;
D'Avolio, Antonio
Co-last
2021

Abstract

Remdesivir is one of the most encouraging treatments against SARS-CoV-2 infection. After intravenous infusion, RDV is rapidly metabolized (T1/2 1h) within the cells to its active adenosine triphosphate analogue form (GS-443902) and, then, it can be found in plasma in its nucleoside analogue form (GS-441524). In this real life study we describe the Remdesivir and GS-441524 concentrations at 3 time points in nine ICU patients, through a validated UHPLC-MS/MS method. The observed data confirmed the very rapid conversion of RDV to its metabolite and the quite long half-life of GS-441524. The mean Cmin , Cmax , AUC0-24 , were < 0.24 ng/mL and 122.3 ng/ml, 2637,3 ng/mL and 157,8 ng/ml, 5171.2 ng*h/mL and 3676.5 ng*h/ml respectively for RDV and GS-441524. Three out of nine patients achieved a Cmax > 2610 ng/mL and 140 ng/mL and AUC0-24 > 1560 ng*h/mL and 2230 ng*h/mL for RDV and GS-441524, respectively. The mean T1/2 value for GS-441524 was 26.3 h. Although the low number of patients, these data can represent an interesting preliminary report of the variability of RDV and GS-441524 concentrations in real-life ICU setting.
1
7
2019n-cov; ICU; covid-19; pharmacokinetics; pneumonia; remdesivir; sars-cov-2
Corcione, Silvia; De Nicolò, Amedeo; Montrucchio, Giorgia; Scabini, Silvia; Avataneo, Valeria; Bonetto, Chiara; Mornese Pinna, Simone; Cusato, Jessica; Canta, Francesca; Urbino, Rosario; Di Perri, Giovanni; Brazzi, Luca; De Rosa, Francesco Giuseppe; D'Avolio, Antonio
File in questo prodotto:
File Dimensione Formato  
156 - 2021 Real-life - Corcione.pdf

Accesso riservato

Tipo di file: PDF EDITORIALE
Dimensione 466.75 kB
Formato Adobe PDF
466.75 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2318/1792787
Citazioni
  • ???jsp.display-item.citation.pmc??? 3
  • Scopus 3
  • ???jsp.display-item.citation.isi??? 4
social impact